Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Operating Leases (2020 - 2025)

10x Genomics (TXG) has disclosed Operating Leases for 6 consecutive years, with $73.4 million as the latest value for Q4 2025.

  • Quarterly Operating Leases changed 0.07% to $73.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.4 million through Dec 2025, changed 0.07% year-over-year, with the annual reading at $73.4 million for FY2025, 0.07% changed from the prior year.
  • Operating Leases hit $73.4 million in Q4 2025 for 10x Genomics, down from $76.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $102.0 million in Q1 2023 to a low of $65.9 million in Q2 2021.
  • Historically, Operating Leases has averaged $83.3 million across 5 years, with a median of $79.4 million in 2021.
  • Biggest five-year swings in Operating Leases: soared 50.21% in 2022 and later fell 23.37% in 2025.
  • Year by year, Operating Leases stood at $76.8 million in 2021, then increased by 12.09% to $86.1 million in 2022, then decreased by 2.66% to $83.8 million in 2023, then fell by 12.55% to $73.3 million in 2024, then rose by 0.07% to $73.4 million in 2025.
  • Business Quant data shows Operating Leases for TXG at $73.4 million in Q4 2025, $76.4 million in Q3 2025, and $77.1 million in Q2 2025.